PBPK Modeling in Adults Enables DDI Risk Assessment in Children with SMA Case Study PBPK Modeling in Adults Enables DDI Risk Assessment in Children with SMA In 2020, the US FDA approved Risdiplam (Evrysdi®) as the first orally administered drug to…Becca Bucci2022年6月2日
Leveraging Clinical Data from One Rare Disease to Support Drug Approval for Another Case Study 希少疾患からの臨床データを活用して、他の疾患の医薬品承認をサポート Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare genetic disease that causes abnormal blood clot…Becca Bucci2022年6月1日
PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials Case Study PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials Genentech was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to…Jim Gallagher2022年4月11日
米国FDAが主導する「プロジェクト・オプティマス」とは? がん治療薬開発にどのような影響を与えるのか? ブログ 米国FDAが主導する「プロジェクト・オプティマス」とは? がん治療薬開発にどのような影響を与えるのか? Project Optimus is an initiative proposed by the U.S. Food and Drug Administration’s Oncology Center…Certara2022年2月2日
What Oncology Drug Developers Should Expect from the FDA’s Project Optimus On-Demand Webinar 米国FDAのプロジェクト・オプティマスががん治療薬の開発者に与える影響 歴史的に、がん治療薬の投与戦略は最大耐容量に焦点が当てられてきました。This…Jim Gallagher2022年1月13日
PBPK Modeling of Antibody-Drug Conjugates – Concept and Application On-Demand Webinar 抗体薬物複合体のPBPKモデリング-概念と応用 Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a…Jim Gallagher2022年1月13日
ScienceDirect: Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial Publication ScienceDirect: Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial Observational studies have postulated a therapeutic role of metformin in treating COVID-19. We conducted ...(cont.)Jim Gallagher2021年12月22日
A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease Blog A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…Certara2021年12月15日
Developing Targeted Covalent Inhibitor Drugs: 3 Key Considerations Blog 標的共有結合阻害薬の開発:3つの検討事項 Traditional mechanisms of drug action rely on the reversible, noncovalent interaction of a ligand with…Certara2021年11月5日
Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award Press Release CertaraのSimcyp™新型コロナウイルス感染症ワクチンモデルがR&D 100アワードを受賞 Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category PRINCETON, NJ…Jim Gallagher2021年10月25日